U.S. Pharmaceuticals & Biotech Most Popular Stocks

FibroGen

Market Cap: US$49.5m

A biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs.

Barinthus Biotherapeutics

Market Cap: US$49.3m

A clinical-stage biopharmaceutical company, focuses on developing immunotherapeutic drug candidates for treating auto-immune and inflammatory diseases.

Cannabist Company Holdings

Market Cap: US$48.9m

The Cannabist Company Holdings Inc. cultivates, manufactures, and sells cannabis products and related services for the medical and adult-use markets in the United States and internationally.

Jupiter Neurosciences

Market Cap: US$48.8m

A clinical stage research and development pharmaceutical company, develops resveratrol platform products for the treatment of neuroinflammation.

Acrivon Therapeutics

Market Cap: US$48.4m

A clinical stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform.

PDS Biotechnology

Market Cap: US$48.4m

A clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies.

Hyperion DeFi

Market Cap: US$48.2m

An ophthalmic technology company, engages in development and commercialization of ophthalmic solutions in the United States.

Medicus Pharma

Market Cap: US$48.2m

A biotech/life sciences company, focuses on developing clinical development programs of therapeutic assets.

Rafael Holdings

Market Cap: US$47.7m

Primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel.

Telomir Pharmaceuticals

Market Cap: US$47.4m

A preclinical-stage biotechnology company, focuses on reversing biological aging and degenerative diseases.

Lantern Pharma

Market Cap: US$46.8m

Focuses on the discovery and development of oncology drug.

Inotiv

Market Cap: US$46.7m

Provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries in the United States, the Netherlands, and internationally.

Maverick Lifestyle

Market Cap: US$45.4m

Engages in the manufacture, branding, marketing, distribution, and sale of products infused with hemp-derived cannabinoids in the United States.

SCYNEXIS

Market Cap: US$45.3m

A biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States.

Cumberland Pharmaceuticals

Market Cap: US$45.3m

A specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally.

House of Jane

Market Cap: US$44.1m

Provides lifestyle therapy products.

Elutia

Market Cap: US$43.7m

A commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation and breast reconstruction in the United States.

Outlook Therapeutics

Market Cap: US$43.3m

Operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications.

RenovoRx

Market Cap: US$42.9m

A clinical-stage biopharmaceutical company, engages in the developing of targeted combination therapies to enhance therapeutic outcomes for cancer patients undergoing treatment.

Estrella Immunopharma

Market Cap: US$42.6m

A clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States.

Grace Therapeutics

Market Cap: US$42.6m

Engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada.

Dyadic International

Market Cap: US$42.3m

A biotechnology platform company, develops, produces, and sells industrial enzymes and other proteins in the United States and internationally.

Century Therapeutics

Market Cap: US$42.1m

A clinical-stage biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases.

CalciMedica

Market Cap: US$42.1m

A clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage.

LAVA Therapeutics

Market Cap: US$41.8m

Operates as a clinical-stage immuno-oncology company that focuses on developing cancer treatments.

Annovis Bio

Market Cap: US$41.5m

A clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States.

Tempest Therapeutics

Market Cap: US$41.3m

A clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer.

Talphera

Market Cap: US$41.1m

A specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings.

Apollomics

Market Cap: US$39.6m

A clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer.

Xilio Therapeutics

Market Cap: US$39.3m

A clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies.

Verrica Pharmaceuticals

Market Cap: US$38.6m

A dermatology therapeutics company, engages in the development and sale of medications for the treatment of skin diseases in the United States.

Generation Bio

Market Cap: US$38.5m

A biotechnology company, discovers, develops, and commercializes redosable therapeutics that reprogram T cells in vivo to reduce or eliminate the production and persistence of autoreactive T cells.

Liminatus Pharma

Market Cap: US$37.7m

Operates as a pre-clinical stage biopharmaceutical company that develops novel cancer therapies.

Provectus Biopharmaceuticals

Market Cap: US$37.1m

A clinical-stage biotechnology company, engages in developing immunotherapy medicines for various diseases in the United States.

Pluri

Market Cap: US$37.0m

A biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and related technologies for various industries.

BioAtla

Market Cap: US$37.0m

A clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer.